Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38530840.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3295.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
KRT17-high intermediate cell population with elevated CXCL8 expression informed elevated myeloid infiltration status in tumors and associated with protumorigenic signatures in peripheral granulocytes from patients with pancreatic cancer. Furthermore, CXCL8 plasma levels were found to resemble KRT17+/CXCL8+ abundance in tumors, in which higher levels predicted worse patient outcomes. See related article by Carpenter et al., p. 2497.
Medical subject headings
- Pancreatic Neoplasms